Shares of Arcturus Therapeutics Holdings Inc. (ARCT) have surged 73% in the past three months compared with the industry’s growth of 10.5%.Last month, the European Commission granted orphan medicinal product designation to the company’s product candidate ARCT-032 for the treatment of cystic fibrosis (CF). The designation is likely to support the development of ARCT-032, including certain protocol assistance, access to the centralized authorization procedure, exemption from fees and research funding, along w ...

While biotech stocks offer some of the most pertinent ideas available in the market, they can be awfully risky. One bad clinical result and boom – there goes your hard-earned money in the toilet. To mitigate the downside risks, it may be better to consider undervalued enterprises.Of course, specifically targeting biotech stocks that trade below their intrinsic or perceived value offers no guarantee of success. Still, given the sometimes extreme mobility that the ecosystem facilitates, it may pay to have cal ...

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today announced that the European Commission (EC), based on a positive opinion issued by the European Medicines Agency (EMA), has granted orphan medicinal product designation for the Company’s produc ...

We’ve all heard the story with AI by now, and for good reason. It has massive potential to overhaul almost every aspect of our lives. With crazy earnings growth expectations over the next few years, it is no wonder that analysts and just about anyone you know are talking about it. Alongside AI, technology in general is an industry with explosive potential. These are highly innovative companies coming out with breakthroughs to fundamentally change how we live. And with low dividend yield rates, these compani ...

Study conducted by Meiji Seika Pharma in Japan Short communication follows previously published data in The Lancet Infectious Diseases demonstrating Immunological Non-Inferiority to Wuhan Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster  New data demonstrates continuous advantage of sa-mRNA over conventional mRNA vaccine in terms of duration of immune response These results follow approval of the world's first sa-mRNA COVID-19 vaccine for adults ...

MarsBars Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is an interesting biotechnology company in the clinical and commercial stages for rare and infectious diseases. Its proprietary platforms, LUNAR for lipid-mediated mRNA delivery and STARR for self-amplifying mRNA technology allowed ARCT to create COVID and influenza vaccines already approved in Japan and with MAA filed in the EU. Also, ARCT is developing game-changing therapies advancing in clinical trials, such as ARCT-810 and ARCT-032 for Ornithin ...

fatido/E+ via Getty Images Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is gearing up to report results from its phase 1b study using its inhaled messenger RNA [mRNA] treatment known as ARCT-032 for the treatment of patients with Cystic Fibrosis [CF]. There is an important catalyst to watch with respect to this program, which is that there will be the release of interim results from this phase 1b study in the 1st half of 2024. What makes this biotech unique is that its approach to treating this patient ...

Therapeutics Holdings Inc. (NASDAQ:ARCT) Q3 2023 Earnings Conference Call November 15, 2023 4:30 PM ET Company Participants Neda Safarzadeh - Vice President, Head of Investor Relations, Public Relations, Marketing Joseph Payne - President and Chief Executive Officer Andrew Sassine - Chief Financial Officer Padmanabh Chivukula - Chief Scientific Officer and Chief Operating Officer Conference Call Participants Yasmeen Rahimi - Piper Sandler Myles Minter - William Blair Seamus Fernandez - Guggenheim Carly Kens ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share ARCT The NASDAQ Stock Market LLC FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q2 2023 Earnings Conference Call August 7, 2023 4:30 PM ET Company Participants Neda Safarzadeh - VP, Head IR, Public Relations and Marketing Joseph Payne - President and CEO Andy Sassine - CFO Pad Chivukula - CSO and COO Conference Call Participants Yasmeen Rahimi - Piper Sandler Myles Minter - William Blair Evan Wang - Guggenheim Securities Pete Stavropoulos - Cantor Fitzgerald Yanan Zhu - Wells Fargo Carly Kenselaar - Citi Thomas Yip - H.C. Wainwright Yal ...